The Phytotherapeutic Fenugreek as Trigger of Toxic Epidermal Necrolysis

Dermatology

Volumn 231, Issue 2, 2015, Pages 99-102

  Bentele Jaberg, Nicoletta ^a   Guenova, Emmanuella ^a   Mehra, Tarun ^b   Nägeli, Mirjam ^a   Chang, Yung Tsan ^a   Cozzio, Antonio ^a   French, Lars E ^a   Hoetzenecker, Wolfram ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Fenugreek; Phytotherapeutics; Toxic epidermal necrolysis

Indexed keywords

DIPYRONE; FENUGREEK EXTRACT; IBUPROFEN; IMMUNOGLOBULIN; PARACETAMOL; PLANT MEDICINAL PRODUCT;

ADULT; BLISTER; CASE REPORT; CELL PROLIFERATION; COMMON COLD; DISEASE SEVERITY; DRUG ERUPTION; DRUG MEGADOSE; EROSION; FEMALE; FENUGREEK; FEVER; GENERAL CONDITION DETERIORATION; HEADACHE; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; INTENSIVE CARE; LACTATION; LYMPHOCYTE TRANSFORMATION TEST; PATCH TEST; PRIORITY JOURNAL; REVIEW; SELF MEDICATION; SKIN BIOPSY; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; ADVERSE EFFECTS; PATHOLOGY; STEVENS-JOHNSON SYNDROME; TRIGONELLA;

ADULT; FEMALE; HUMANS; PLANT PREPARATIONS; STEVENS-JOHNSON SYNDROME; TRIGONELLA;

EID: 84939575353     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000433423     Document Type: Review

References (32)

1. French LE, Prins C. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis; in Bolognia JL, Jorrizo JL, Schaffer JV (eds). Dermatology, ed 3. New York, Elsevier, 2013, vol 3, pp 319-334
2. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome. does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136. 323-327
3. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333. 1600-1607
4. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN. a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115. 149-153
5. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004; 140. 890-892
6. Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, Grange A, Amarger S, Girardin P, Guinnepain MT, Truchetet F, Lasek A, Waton J; Toxidermies group of the French Society of Dermatology. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 2013; 168. 555-562
7. Abe R. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis. J Dermatol 2015; 42. 42-48
8. Yun J, Marcaida MJ, Eriksson KK, Jamin H, Fontana S, Pichler WJ, Yerly D. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLAB 58. 01. J Immunol 2014; 192. 2984-2993
9. Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, Miles JJ, Kjer-Nielsen L, Gras S, Williamson NA, Burrows SR, Purcell AW, Rossjohn J, McCluskey J. Immune selfreactivity triggered by drug-modified HLApeptide repertoire. Nature 2012; 486. 554-558
10. Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, Oseroff C, Lu S, Jakoncic J, de Oliveira CA, Yang L, Mei H, Shi L, Shabanowitz J, English AM, Wriston A, Lucas A, Phillips E, Mallal S, Grey HM, Sette A, Hunt DF, Buus S, Peters B. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 2012; 109. 9959-9964
11. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLAB 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102. 4134-4139
12. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7. 317-323
13. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics. a marker for Stevens-Johnson syndrome. Nature 2004; 428. 486
14. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282. 490-493
15. Wehrli P, Viard I, Bullani R, Tschopp J, French LE. Death receptors in cutaneous biology and disease. J Invest Dermatol 2000; 115. 141-148
16. Ito K, Hara H, Okada T, Shimojima H, Suzuki H. Toxic epidermal necrolysis treated with lowdose intravenous immunoglobulin. immunohistochemical study of Fas and Fas-ligand expression. Clin Exp Dermatol 2004; 29. 679-680
17. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14. 1343-1350
18. Saito N, Qiao H, Yanagi T, Shinkuma S, Nishimura K, Suto A, Fujita Y, Suzuki S, Nomura T, Nakamura H, Nagao K, Obuse C, Shimizu H, Abe R. An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci Transl Med 2014; 6. 245ra295
19. Viard-Leveugle I, Bullani RR, Meda P, Micheau O, Limat A, Saurat JH, Tschopp J, French LE. Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. J Biol Chem 2003; 278. 16183-16188
20. Enk A, Fierlbeck G, French L, Hertl M, Messer G, Meurer M, Steinbrink K, Stingl G, Volc-Platzer B, Zillikens D. Use of high-dose immunoglobulins in dermatology. J Dtsch Dermatol Ges 2009; 7. 806-812
21. Lee HY, Lim YL, Thirumoorthy T, Pang SM. The role of intravenous immunoglobulin in toxic epidermal necrolysis. a retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol 2013; 169. 1304-1309
22. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis. a systematic review and meta-analysis. Br J Dermatol 2012; 167. 424-432
23. Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maitre B, Revuz J, Bagot M, Roujeau JC. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010; 163. 847-853
24. Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol 2014; 71. 941-947
25. Patil SP, Niphadkar PV, Bapat MM. Allergy to fenugreek (Trigonella foenum graecum) . Ann Allergy Asthma Immunol 1997; 78. 297-300
26. Vinje NE, Namork E, Lovik M. Cross-allergic reactions to legumes in lupin and fenugreeksensitized mice. Scand J Immunol 2012; 76. 387-397
27. Kumar Das K, Khondokar S, Rahman A, Chakraborty A. Unidentified drugs in traditional medications causing toxic epidermal necrolysis. a developing country experience. Int J Dermatol 2014; 53. 510-515
28. Monk B. Severe cutaneous reactions to alternative remedies. Br Med J (Clin Res Ed) 1986; 293. 665-666
29. Mochitomi Y, Inoue A, Kawabata H, Ishida S, Kanzaki T. Stevens-Johnson syndrome caused by a health drink (Eberu) containing ophiopogonis tuber. J Dermatol 1998; 25. 662-665
30. Shivamurthy RP, Kallappa R, Reddy SG, Rangappa DK. Stevens-Johnson syndrome due to unknown drugs. Indian J Pharmacol 2012; 44. 134-135
31. Wu ML, Deng JF. Toxic epidermal necrolysis after extensive dermal use of realgar-containing (arsenic sulfide) herbal ointment. Clin Toxicol (Phila) 2013; 51. 801-803
32. Wechwithan S, Suwankesawong W, Sornsrivichai V, McNeil EB, Jiraphongsa C, Chongsuvivatwong V. Signal detection for Thai traditional medicine. examination of national pharmacovigilance data using reporting odds ratio and reported population attributable risk. Regul Toxicol Pharmacol 2014; 70. 407-412